An FDA panel raised concerns about the safety of antidepressants (SSRIs) during pregnancy, but doctors are pushing back, arguing that these medications are often essential for treating perinatal depression. The panel's stance has sparked controversy, as experts worry it could discourage women from seeking necessary mental health care.

Editor’s Note: This story matters because misinformation about medication safety—especially during pregnancy—can have real consequences. If women avoid SSRIs based on unclear guidance, it could worsen maternal mental health, which is already a critical issue. Doctors are frustrated because the panel's doubts might overshadow well-established benefits of these treatments.